Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

Nevertheless, really good money to be made for those brave enough!

Yep good money at the end of the day.

You cashed in yet mitzy or you waiting for the 100 ?

:-)

still hold will hold for 50p.

Holding up well today which is great because this is ridiculously cheap.

Up and away..

I'm kicking myself I passed on this one! I put NYO and FTE in my isa today--are you in those Mitzy?

Yep holding from 20p moneyplus could rocket to a couple of quid or go bust...will see.

Dear me its down 10%..

Are the wheels coming away now ?

Maybe Tara will have to start a Angle 500 a share thread to get it back up :-))

lol..

Where is Tara today..lol.

Guys this is going all the way.

Wow this is great up 23% and more.

down 15% lol.

Course it's going down, most of the profits were made from a profit on a PXS sale,
now to keep making those kind of profits they need to keep finding a stock that did what Pxs did which was 1p or less upto a 23p high, you need a crystal ball to do that every 6 months and would be lucky to that every six years, a huge pump and dump that has completely fizzled out and now the stock will only attract day traders trying to skim on the bounces intraday.

Part of an email I received today morning:

...Angle aims to secure a deal for its other major investment, 78%-owned Parsortix, by April 2011. Parsortix has developed the first ever non-invasive testing platform for the unborn baby. Pregnant women have a very small number of their baby's cells circulating in their blood; at most one foetal cell for 500 million maternal cells. Parsortix has developed a separation device, which can isolate intact foetal cells in maternal blood (as opposed to merely DNA fragments) when only 1.5ml of maternal blood is flowed through the device. The current method of testing carries substantial risk for both mother and baby, and is limited to high risk category patients where an invasive procedure can be justified.

Parsortix's method would be both cheaper and safer than conventional testing, so the market potential is pretty obvious. In the US market alone there are currently 375,000 such invasive tests undertaken per annum leaving the remaining 2.2 million pregnancies with no advance warning of potential problems. Assuming 11 million births per annum in industrialised countries and a cost of $200 per test, capturing just 3% of this market would generate substantial royalties (at 15%: c.$10 million per annum). News of a commercial partner for this technology on the lines of the Novocellus deal could drive the shares sharply higher in the near future. Buy. http://uk-analyst.com/shop/page-article/action-article.show/id-130003216

those in before today's hike should consider selling and buying back later!!! :-))))

WH Ireland note:
"ANGLE has announced that its 85% owned US-based portfolio company, Parsortix Inc. has completed a study demonstrating that its cell separation device reproducibly isolates and captures tumour cells in cancer patient blood, and emphasises that the cancer cells can be identified within the device without requiring a complicated cell extraction process. These are highly promising findings, which ANGLE believes give the technology an immediate market application in cancer research enabling sales of the product for research purposes from the second half of 2012.
Following this, the next step is to replicate these results in larger clinical trials to obtain US and European regulatory marketing approvals, which would enable Parsortix Inc. to sell the technology as a cost-effective, non-invasive, reliable screening tool to improve cancer treatment through early detection of cancer and monitoring of cancer patients while receiving treatment and those in remission. ANGLE estimates that the addressable clinical market for a simple circulating tumour cells counting device in the US alone exceeds $4 billion per annum."